Thus, based on such a large number of clinical trial results, multiple countries have successively approved SGLT-2 inhibitors for the treatment of CKD (Herrington et al., 2021; Administration USFD Home-News, 2024; Agency, 2024; Astrazeneca, 2024). Here, SLC5A2 is linked to chronic kidney disease.